Evidence map›Paper›PMID 32021276›Full record

ArticleOncoTargets and therapy2020

Icariin Mitigates the Growth and Invasion Ability of Human Oral Squamous Cell Carcinoma via Inhibiting Toll-Like Receptor 4 and Phosphorylation of NF-κB P65.

Ke Lei, Bing Ma, Ping Shi, Che Jin, Tan Ling, Longjiang Li, Xiangyi He, Lunchang Wang

RetractedOpen access · goldAbstract readRetracted Publication
PubMed Full text at PMC Publisher
In one paragraph

Article in OncoTargets and therapy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.9field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Article
  6. Review
  7. Article
  8. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 1 country.

Ke LeiDepartment of Stomatology, Central Hospital of Guangyuan, Guangyuan 628000, People's Republic of China.
Bing MaDepartment of Respiratory, Central Hospital of Guangyuan, Guangyuan 628000, People's Republic of China.
Ping ShiDepartment of Respiratory, Central Hospital of Guangyuan, Guangyuan 628000, People's Republic of China.
Che JinEndodontics Department, Dental Hospital of Lanzhou, Lanzhou 730000, People's Republic of China.
Tan LingDepartment of Stomatology, Central Hospital of Guangyuan, Guangyuan 628000, People's Republic of China.
Longjiang LiState Key Laboratory of Oral Diseases, Sichuan University, Chengdu 610041, People's Republic of China.
Xiangyi HeDepartment of Prosthodontics, School of Stomatology, Lanzhou University, Lanzhou 730000, People's Republic of China.
Lunchang WangDepartment of Stomatology, Central Hospital of Guangyuan, Guangyuan 628000, People's Republic of China.
Taiyuan Central Hospital · CNLanzhou University · CNPulmonary Hospital of Lanzhou · CNState Key Laboratory of Oral Diseases

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundOral squamous cell carcinoma (OSCC) is an aggressive malignancy worldwide. Icariin (ICA), an active ingredient of flavonoids, has been demonstrated to possess antitumor activity in diverse cancers. Whereas, the role of ICAin OSCC is still unclear.

methodsHerein, we investigated the anti-tumor effects of ICA in vitro and in vivo. CCK-8, colony formation and trans-well assay were used to examined viability, proliferation and invasion in SCC-9 and SCC-15 cell lines, respectively. Next, we tested the expression of toll-like receptor 4 (TLR4) and NF-κB P65 by western blot or immunofluorescence staining. Finally, we constructed a xenograft mice model to investigate the effect of ICA in vivo.

resultsIn vitro, ICA decreased the human oral squamous cells viability, proliferation and invasion in a concentration-dependent manner. Besides, ICA decreased the phosphorylation level of P65 and down-regulated TLR4 protein. In vivo, compared with control, ICA significantly suppressed the tumor size and weight. In addition, ICA downregulated the levels of Ki67 and VEGF markedly. Dramatically, ICA decreased the phosphorylation level of P65 in tumor tissues.

conclusionTaken together, ICA could act as a anticancer drug against OSCC to mitigate the growth and invasion ability, the underlying mechanism may due to the down-regulation of TLR4/NF-κB signaling.

Indexed as

icariinNF-κBoral squamous cell carcinomastoll-like receptor 4

Identifiers

PMID32021276
PMCPMC6971293
OpenAlexW2999706052

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.